Bullboard - Stock Discussion Forum Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug,... see more

Add To Watchlist

GREY:ATBPF - Post Discussion

Antibe Therapeutics Inc(Pre-Merger) > Zacks Small-Cap Research Report - ATBPF - 22Nov22

View:

Post by davgro on Nov 23, 2022 11:05pm

Zacks Small-Cap Research Report - ATBPF - 22Nov22

Here is a link to a PDF copy of the most recent Zacks Small-Cap Research Report for ATBPF released on November 22, 2022.

Conclusion:

"The new formulation for otenaproxesul is an exciting development for the company as it not only should lead to lower dosing but also extends the IP protection out to 2042. We look forward to the initiation of the Phase 2 bunionectomy trial in the first half of 2023. Investors should be aware that with the short duration of acute pain trials, the development pathway for otenaproxesul could potentially be completed in 12-18 months. Lastly, the company is expected to select a lead development candidate for the inflammatory bowel disease program before the end of 2022, which offers upside to the story. We have made no changes to our model and our valuation remains at $4.00 per share."

Zacks Small-Cap Research Report - ATBPF - 22Nov22

340